San Francisco, CA – endpoint, a leading interactive response technology (IRT) solutions company, has been selected as the sole IRT provider for Ferring Pharmaceuticals AS, a biopharmaceutical company based in Denmark.
endpoint’s partnership with Ferring Pharmaceuticals began in early 2015. “We had been searching for an IRT partner with innovative, adaptable and tailored solutions that matched our diverse trial designs and met our needs during the implementation of IRT as a solution for the clinical supply chain,” said Susan Kampmann, associate director, Ferring Pharmaceuticals. “The endpoint team was able to provide this exact technology solution, accompanied by continuous guidance and consultation from our endpoint project team to bring efficiencies to our day-to-day trial operations.”
endpoint continues to grow in Europe by offering customizable solutions through PULSE, a full-service IRT solution, and through DRIVE, an enterprise supply management hub that provides the benefits of IRT supplies management for non-IRT studies and investigator initiated trials.
“The endpoint-Ferring preferred partnership is a prime example of endpoint’s expansion across the global clinical trials industry,” said Chuck Harris, endpoint’s CEO. “endpoint seeks to redefine IRT by thoroughly understanding the growing complexities of clinical trials; we provide the most innovative novel solutions to meet those challenges across all geographies and therapeutic areas.”
Read more about endpoint’s proven solutions at endpointclinical.com.
About endpoint
endpoint provides interactive response technology (IRT) systems and solutions that support the life sciences industry. endpoint’s proprietary IRT system configuration engine, PULSE, provides non-technical users with the necessary tools to design and deploy customized IRT solutions in just four weeks. endpoint is headquartered in San Francisco and has been developing IRT systems since 2009. See how its flexible IRT solution meets the unique needs of any clinical trial at www.endpointclinical.com.
About Ferring Pharmaceuticals
Headquartered in Saint-Prex, Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. Ferring has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. To learn more about Ferring or its products, please visit www.ferring.com.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.